LipoScience, Inc.
🏢 View company profile →36Patents
31Active
36Granted
52Portfolio score
Filing activity: Apr 19, 2000 → Jan 4, 2022 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6576471B2 | Methods, systems, and computer program products for analyzing and presenting NMR lipoprotein-based risk assessment results | Emerging Cross-Sectional Technologies | 42 | Expired |
| US6518069B1 | Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6617167B2 | Method of determining presence and concentration of lipoprotein X in blood plasma and serum | Emerging Cross-Sectional Technologies | 29 | Expired |
| US7243030B2 | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals | Physics | 29 | Expired |
| US7790465B2 | Methods, systems and computer programs for assessing CHD risk using adjusted LDL particle number measurements | Emerging Cross-Sectional Technologies | 24 | Active |
| US8386187B2 | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same | Emerging Cross-Sectional Technologies | 12 | Active |
| US8013602B2 | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples | Physics | 11 | Active |
| US6653140B2 | Methods for providing personalized lipoprotein-based risk assessments | Emerging Cross-Sectional Technologies | 11 | Expired |
| US9361429B2 | Multi-parameter diabetes risk evaluations | Physics | 11 | Active |
| US9792410B2 | Multi-parameter diabetes risk evaluations | Physics | 8 | Active |
| US10388414B2 | Multi-parameter diabetes risk evaluations | Physics | 6 | Active |
| US9435870B2 | Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements | Physics | 5 | Active |
| US9470771B2 | NMR measurements of NMR biomarker GlycA | Physics | 5 | Active |
| US8704521B2 | NMR analyzers for clinical evaluation of biosamples | Physics | 4 | Active |
| US9952232B2 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | Physics | 4 | Active |
| US9483612B2 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | Physics | 4 | Active |
| US10386355B2 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | Physics | 3 | Active |
| US10365339B2 | NMR analyzers for clinical evaluation of biosamples | Physics | 3 | Active |
| US9483611B2 | Protective HDL particle number evaluations | Physics | 2 | Active |
| US9535144B2 | NMR quantification of TMAO | Physics | 2 | Active |
| US9541620B2 | NMR quantification of TMAO | Physics | 2 | Active |
| US10852293B2 | NMR measurements of NMR biomarker GlycA | Physics | 2 | Active |
| US11156621B2 | Multi-parameter metabolic vulnerability index evaluations | Physics | 1 | Active |
| US11231429B2 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | Physics | 1 | Active |
| US9689942B2 | Quantitative NMR clinical analyzers with automatic NMR temperature sensitivity compensation that accommodate large ambient operational temperature ranges | Physics | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.